gout
Conditions
Interventions
Experimental group:Gout analgesic granule and Uricurate granule
The control group:Colchicine tablets and Benzbromarone tablet
Sponsors
Yunnan Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 2.1 Inclusion criteria of acute stage: ? Meet the diagnostic criteria of acute gout arthritis in Western medicine;(2) in the acute stage, it meets the requirement of dampness and heat;(3) patients who were not treated with other drugs and methods at the time of onset;Those who volunteered to participate in the study and agreed to enter the clinical study, and those who signed the informed consent.2.2 Inclusion criteria for intermittent therapy: ? Patients with pain VAS =2 and blood uric acid =420µmol/L were included in intermittent therapy;? Patients with spleen deficiency and dampness resistance were assigned to the Chinese medicine group, while the rest were assigned to the Western medicine group.
Exclusion criteria
Exclusion criteria: ? Those who do not meet the above inclusion criteria;? Secondary gout, arthritis caused by rheumatoid arthritis, suppurative arthritis, traumatic arthritis, silver arthritis, pseudogout, lupus erythematosus and other diseases.Chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy and other joint lesions;? Acute joint pain was unbearable (grade 10);? Long-term use of the following drugs, such as dihydrokeuride, furosemide, risuric acid, pyrazinamide, low-dose aspirin, and drugs containing the above ingredients, such as compound antihypertensive tablets, caused by gout;? Allergic constitution, known to be allergic to the composition of the drug;? Pregnant and lactating women;? Mental patients;(8) Suspected or have a history of alcohol or drug abuse, or other diseases that, according to the judgment of the investigator, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in the work environment and other conditions that are easy to cause loss of follow-up;? Severe complications of heart, brain, liver, kidney or other serious primary diseases;? blood ALT, AST, Cr more than 1 times the normal value;11 Patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood sedimentation;Urinary uric acid;C-reactive protein;Blood sugar;Blood fat;renal function;Liver function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine urine;Feces regular;Routine blood; | — |
Countries
China
Contacts
Public ContactPeng Jiangyun
Outcome results
None listed